EUCTR2004-002609-66-IT进行中（未招募）不适用
A phase 3, randomized, open-label, two-arm, parallel-group, multicenter, multinational trial to compare the efficacy of rotigotine transdermal patch to that of ropinirole on early morning motor impairment and sleep disorders in subjects with early-stage, idiopathic Parkinson s disease
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
A phase 3, randomized, open-label, two-arm, parallel-group, multicenter, multinational trial to compare the efficacy of rotigotine transdermal patch to that of ropinirole on early morning motor impairment and sleep disorders in subjects with early-stage, idiopathic Parkinson's diseaseParkinson's DiseaseEUCTR2004-002609-66-DESchwarz Biosciences GmbH60
招募中
3 期
It is a two arm phase III study of double vs single therapy in pancreatic cancer for those who have failed chemotherapy(first line treatment)CTRI/2022/02/040235Tata Memorial Hospital
撤回
不适用
A randomized study in Maori / Pacific Islander smokers comparing exposure to selected harmful and potentially harmful constituents (HPHCs) of those switching to the iQOS device, continuing with conventional cigarette smoking and smoking abstinence.SmokingPublic Health - Other public healthMental Health - AddictionACTRN12617000232336Optimal Clinical Trials180
进行中（未招募）
1 期
A study of efficacy and safety of LAG525 in combination with spartalizumab, or with spartalizumab and carboplatin, or with carboplatin, in patients with advanced triple-negative breast cancer.EUCTR2017-004865-28-FRovartis Pharma AG96
进行中（未招募）
1 期
A study of efficacy and safety of LAG525 in combination with spartalizumab, or with spartalizumab and carboplatin, or with carboplatin, in patients with advanced triple-negative breast cancer.Triple negative breast cancerMedDRA version: 20.0Level: LLTClassification code 10072740Term: Locally advanced breast cancerSystem Organ Class: 100000004864EUCTR2017-004865-28-ESovartis Farmacéutica, S.A88